Which has preferable earnings & valuation, SEPN or ERAS?

Septerna has higher revenue and earnings than Erasca. Septerna is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 31.60 -$48.88M -$0.81 N/A Erasca N/A N/A -$124.55M -$0.93 N/A

Is SEPN or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -49.88% -12.72% -8.87% Erasca N/A -35.31% -29.49%

Does the media prefer SEPN or ERAS?

In the previous week, Erasca had 40 more articles in the media than Septerna. MarketBeat recorded 42 mentions for Erasca and 2 mentions for Septerna. Septerna's average media sentiment score of 0.37 beat Erasca's score of 0.13 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 4 Very Positive mention(s) 3 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, SEPN or BLTE?

Septerna has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 31.60 -$48.88M -$0.81 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is SEPN or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -49.88% -12.72% -8.87% Belite Bio N/A -13.14% -12.88%

Does the media prefer SEPN or BLTE?

In the previous week, Belite Bio had 4 more articles in the media than Septerna. MarketBeat recorded 6 mentions for Belite Bio and 2 mentions for Septerna. Septerna's average media sentiment score of 0.37 beat Belite Bio's score of 0.27 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SEPN or TWST?

In the previous week, Twist Bioscience had 4 more articles in the media than Septerna. MarketBeat recorded 6 mentions for Twist Bioscience and 2 mentions for Septerna. Twist Bioscience's average media sentiment score of 0.55 beat Septerna's score of 0.37 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNTH or SEPN?

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Septerna. MarketBeat recorded 4 mentions for Dianthus Therapeutics and 2 mentions for Septerna. Septerna's average media sentiment score of 0.37 beat Dianthus Therapeutics' score of 0.33 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMRX or SEPN?

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 2 mentions for Septerna. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat Septerna's score of 0.37 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Septerna (SEPN) Competitors

$32.21 -1.19 (-3.56%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$32.22 +0.02 (+0.05%)

As of 07/20/2026 07:34 PM Eastern

Compare

SEPN vs. ERAS, BLTE, TWST, DNTH, and AMRX

Should you buy Septerna stock or one of its competitors? MarketBeat compares Septerna with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Septerna include Erasca (ERAS), Belite Bio (BLTE), Twist Bioscience (TWST), Dianthus Therapeutics (DNTH), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Septerna compare to Erasca?

Septerna (NASDAQ:SEPN) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Septerna has higher revenue and earnings than Erasca. Septerna is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	31.60	-$48.88M	-$0.81	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Erasca has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Erasca	N/A	-35.31%	-29.49%

67.8% of Erasca shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Septerna currently has a consensus target price of $45.89, indicating a potential upside of 42.47%. Erasca has a consensus target price of $21.64, indicating a potential upside of 14.96%. Given Septerna's stronger consensus rating and higher probable upside, research analysts clearly believe Septerna is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Erasca has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Erasca had 40 more articles in the media than Septerna. MarketBeat recorded 42 mentions for Erasca and 2 mentions for Septerna. Septerna's average media sentiment score of 0.37 beat Erasca's score of 0.13 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	4 Very Positive mention(s)	3 Positive mention(s)	31 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Septerna beats Erasca on 10 of the 15 factors compared between the two stocks.

How does Septerna compare to Belite Bio?

Septerna (NASDAQ:SEPN) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

0.5% of Belite Bio shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

In the previous week, Belite Bio had 4 more articles in the media than Septerna. MarketBeat recorded 6 mentions for Belite Bio and 2 mentions for Septerna. Septerna's average media sentiment score of 0.37 beat Belite Bio's score of 0.27 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Septerna presently has a consensus target price of $45.89, indicating a potential upside of 42.47%. Belite Bio has a consensus target price of $203.00, indicating a potential upside of 32.82%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Septerna has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	31.60	-$48.88M	-$0.81	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Belite Bio has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Belite Bio	N/A	-13.14%	-12.88%

Summary

Septerna beats Belite Bio on 12 of the 16 factors compared between the two stocks.

How does Septerna compare to Twist Bioscience?

Septerna (NASDAQ:SEPN) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Twist Bioscience has a net margin of -19.85% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Septerna presently has a consensus target price of $45.89, indicating a potential upside of 42.47%. Twist Bioscience has a consensus target price of $90.30, indicating a potential upside of 3.26%. Given Septerna's stronger consensus rating and higher probable upside, equities analysts clearly believe Septerna is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market.

In the previous week, Twist Bioscience had 4 more articles in the media than Septerna. MarketBeat recorded 6 mentions for Twist Bioscience and 2 mentions for Septerna. Twist Bioscience's average media sentiment score of 0.55 beat Septerna's score of 0.37 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	31.60	-$48.88M	-$0.81	N/A
Twist Bioscience	$376.57M	14.46	-$77.67M	-$1.33	N/A

Summary

Septerna beats Twist Bioscience on 10 of the 14 factors compared between the two stocks.

How does Septerna compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Septerna (NASDAQ:SEPN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 5.8% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dianthus Therapeutics currently has a consensus price target of $117.82, suggesting a potential upside of 16.65%. Septerna has a consensus price target of $45.89, suggesting a potential upside of 42.47%. Given Septerna's higher probable upside, analysts plainly believe Septerna is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Septerna. MarketBeat recorded 4 mentions for Dianthus Therapeutics and 2 mentions for Septerna. Septerna's average media sentiment score of 0.37 beat Dianthus Therapeutics' score of 0.33 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Septerna has higher revenue and earnings than Dianthus Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,706.70	-$162.34M	-$4.13	N/A
Septerna	$45.95M	31.60	-$48.88M	-$0.81	N/A

Dianthus Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Septerna has a net margin of -49.88% compared to Dianthus Therapeutics' net margin of -12,998.50%. Septerna's return on equity of -12.72% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Septerna	-49.88%	-12.72%	-8.87%

Summary

Septerna beats Dianthus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Septerna compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Septerna (NASDAQ:SEPN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Amneal Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.85	$72.06M	$0.38	46.05
Septerna	$45.95M	31.60	-$48.88M	-$0.81	N/A

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 2 mentions for Septerna. Amneal Pharmaceuticals' average media sentiment score of 1.12 beat Septerna's score of 0.37 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of Septerna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Septerna	-49.88%	-12.72%	-8.87%

Amneal Pharmaceuticals currently has a consensus target price of $16.60, suggesting a potential downside of 5.14%. Septerna has a consensus target price of $45.89, suggesting a potential upside of 42.47%. Given Septerna's stronger consensus rating and higher possible upside, analysts plainly believe Septerna is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Amneal Pharmaceuticals beats Septerna on 10 of the 17 factors compared between the two stocks.

Get Septerna News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEPN vs. The Competition

Export

Metric	Septerna	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.51B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-39.76	20.49	27.06	23.94
Price / Sales	31.60	300.39	517.51	91.94
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	3.78	7.92	10.66	6.14
Net Income	-$48.88M	$23.81M	$3.60B	$331.74M
7 Day Performance	-6.75%	-1.09%	-1.23%	-1.81%
1 Month Performance	-10.95%	2.56%	1.10%	-1.44%
1 Year Performance	161.66%	42.16%	23.65%	16.33%

Septerna Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEPN Septerna	2.169 of 5 stars	$32.21 -3.6%	$45.89 +42.5%	+156.7%	$1.51B	$45.95M	N/A	N/A
ERAS Erasca	1.8057 of 5 stars	$19.50 +8.9%	$20.30 +4.1%	+1,154.7%	$6.06B	N/A	N/A	120	Trending News Analyst Forecast
BLTE Belite Bio	3.334 of 5 stars	$146.68 -0.2%	$203.00 +38.4%	+150.9%	$5.88B	N/A	N/A	10	News Coverage
TWST Twist Bioscience	2.0931 of 5 stars	$92.53 +2.4%	$87.30 -5.7%	+148.6%	$5.76B	$376.57M	N/A	990	Gap Up
DNTH Dianthus Therapeutics	1.9496 of 5 stars	$101.28 +2.7%	$117.82 +16.3%	+395.1%	$5.54B	$2.04M	N/A	80	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEPN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Septerna (SEPN) Competitors

SEPN vs. ERAS, BLTE, TWST, DNTH, and AMRX

How does Septerna compare to Erasca?

Summary

How does Septerna compare to Belite Bio?

Summary

How does Septerna compare to Twist Bioscience?

Summary

How does Septerna compare to Dianthus Therapeutics?

Summary

How does Septerna compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Septerna (SEPN) Competitors

SEPN vs. ERAS, BLTE, TWST, DNTH, and AMRX

How does Septerna compare to Erasca?

Which has preferable earnings & valuation, SEPN or ERAS?

Is SEPN or ERAS more profitable?

Do institutionals and insiders have more ownership in SEPN or ERAS?

Do analysts rate SEPN or ERAS?

Which has more volatility & risk, SEPN or ERAS?

Does the media prefer SEPN or ERAS?

Summary

How does Septerna compare to Belite Bio?

Do institutionals & insiders have more ownership in SEPN or BLTE?

Which has more risk and volatility, SEPN or BLTE?

Does the media prefer SEPN or BLTE?

Do analysts recommend SEPN or BLTE?

Which has stronger valuation & earnings, SEPN or BLTE?

Is SEPN or BLTE more profitable?

Summary

How does Septerna compare to Twist Bioscience?

Is SEPN or TWST more profitable?

Do analysts prefer SEPN or TWST?

Which has more risk and volatility, SEPN or TWST?

Does the media favor SEPN or TWST?

Which has better valuation & earnings, SEPN or TWST?

Summary

How does Septerna compare to Dianthus Therapeutics?

Do institutionals & insiders have more ownership in DNTH or SEPN?

Do analysts recommend DNTH or SEPN?

Does the media favor DNTH or SEPN?

Which has preferable valuation & earnings, DNTH or SEPN?

Which has more risk and volatility, DNTH or SEPN?

Is DNTH or SEPN more profitable?

Summary

How does Septerna compare to Amneal Pharmaceuticals?

Which has better earnings & valuation, AMRX or SEPN?

Does the media refer more to AMRX or SEPN?

Do institutionals and insiders have more ownership in AMRX or SEPN?

Which has more risk and volatility, AMRX or SEPN?

Is AMRX or SEPN more profitable?

Do analysts rate AMRX or SEPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools